FDA CRL - CIPLA USA INC

Cipla USA, Inc., acting as the U.S. Agent for Cipla Limited, India, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its New Drug Application (NDA 210168). The FDA determined that the application cannot be approved in its current state. The primary reason for this action is unstated "PRODUCT QUALITY" deficiencies. The letter indicates that comments on the proposed Prescribing Information and Carton and Container Labeling are reserved until the application is otherwise deemed adequate, implying these are secondary to the product quality concerns. Under regulatory framework 21 CFR 314.110, Cipla is required to resubmit or take other actions within one year to address the identified issues. A resubmission must fully resolve all deficiencies outlined in the CRL and must be clearly labeled as a "RESUBMISSION." The FDA also advises that a partial response will not initiate a new review cycle. Cipla has the option to request a meeting or teleconference with the FDA to discuss the necessary steps before the application can achieve approval. The document explicitly states that the drug product may not be legally marketed until written approval from the FDA is granted. This CRL underscores the need for comprehensive remediation of product quality issues to meet regulatory standards.